BIOPHYTIS - Live Healthier Longer Email Format
Biotechnology ResearchÎle-de-france, France11-50 Employees
BIOPHYTIS - Live Healthier Longer is a clinical-stage biotechnology company focused on developing therapeutics aimed at slowing aging-related degenerative processes by enhancing the body's resilience to stress. Its leading candidate, Ruvembri, is an orally administered drug in regulatory and clinical development for two indications: severe respiratory events associated with COVID-19, supported by Phase 2/3 COVA data, and reduced mobility in elderly patients with sarcopenia, with Phase 2 results from the SARA program conducted in the United States and Europe. A pediatric formulation of Ruvembri is under development for Duchenne Muscular Dystrophy (MYODA), with IND clearances granted in the United States and Belgium. The company is based in Paris, in the Île-de-France region, and operates within the biotechnology research industry targeting age-related conditions. In recent activity, BIOPHYTIS has participated in industry events such as Longevity Summit 2026 and has pursued AI-enabled drug discovery collaborations with Nebius Group and LynxKite to accelerate longevity programs.
1-888-653-2347 
support@leadiq.com 
